NCT06531291View on ClinicalTrials.gov

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 10, 2024

Primary Completion Date

August 9, 2027

Study Completion Date

August 9, 2027

Conditions
ESCCBiliary Tract CancerGastric CancerPancreas Cancer
Interventions
DRUG

Surufatinib

250 mg, po, qd, q3w

DRUG

Serplulimab

200 mg, iv, d1, q3w

DRUG

standard chemotherapy

Decided by PI

Trial Locations (1)

200127

Renji hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT06531291 - Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | Biotech Hunter | Biotech Hunter